Emerging Minimally Invasive Treatment Options for Male Lower Urinary Tract Symptoms[Figure presented]

European Urology

Volumn 72, Issue 6, 2017, Pages 986-997

  Magistro, Giuseppe ^a   Chapple, Christopher R ^b   Elhilali, Mostafa ^c   Gilling, Peter ^d   McVary, Kevin T ^e   Roehrborn, Claus G ^f   Stief, Christian G ^a   Woo, Henry H ^g   Gratzke, Christian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d TAURANGA HOSPITAL   (New Zealand)

^e SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Benign prostatic hyperplasia; Convective water vapour energy; Intraprostatic injection; Male lower urinary tract symptoms; Minimally invasive treatment; Prostatic artery embolization; Prostatic urethral lift; Temporary implantable nitinol device; Waterjet ablation

Indexed keywords

BOTULINUM TOXIN A; FEXAPOTIDE; TOPSALYSIN; BACTERIAL TOXIN; NEUROTOXIN; PORE FORMING CYTOTOXIC PROTEIN;

ARTERIAL EMBOLIZATION; CLINICAL OUTCOME; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERVENTIONAL RADIOLOGIST; LOCAL ANESTHESIA; LOWER URINARY TRACT SYMPTOM; MINIMALLY INVASIVE PROCEDURE; MORBIDITY; PATIENT SAFETY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROBOTICS; SEXUAL FUNCTION; SYSTEMATIC REVIEW; WATER VAPOR; ABLATION THERAPY; ADVERSE DEVICE EFFECT; ARTIFICIAL EMBOLIZATION; COMPLICATION; INJECTION; MALE; MINIMALLY INVASIVE SURGERY; PROSTHESES AND ORTHOSES;

ABLATION TECHNIQUES; BACTERIAL TOXINS; BOTULINUM TOXINS, TYPE A; EMBOLIZATION, THERAPEUTIC; HUMANS; INJECTIONS; LOWER URINARY TRACT SYMPTOMS; MALE; MINIMALLY INVASIVE SURGICAL PROCEDURES; NEUROTOXINS; PORE FORMING CYTOTOXIC PROTEINS; PROSTATIC HYPERPLASIA; PROSTHESES AND IMPLANTS;

EID: 85024827230     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2017.07.005     Document Type: Review

References (86)

1. Vuichoud, C., Loughlin, K.R., Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol 22:Suppl 1 (2015), 1–6.
2. Parsons, J.K., Wilt, T.J., Wang, P.Y., et al. Progression of lower urinary tract symptoms in older men: a community based study. J Urol 183 (2010), 1915–1920.
3. Centers for Disease Control and Prevention, Public health and aging: trends in aging–United States and worldwide. JAMA 289 (2003), 1371–1373.
4. Gravas S, Bach T, Bachmann A, et al. EAU Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). 2015. http://uroweb.org/wp-content/uploads/EAU-Guidelines-Management-of-non-neurogenic-male-LUTS-2016.pdf.
5. McVary KT RC, Avins AL. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH); American Urological Association Education and Research, Inc. 2010. http://www.auanet.org/guidelines.
6. Bach, T., Muschter, R., Sroka, R., et al. Laser treatment of benign prostatic obstruction: basics and physical differences. Eur Urol 61 (2012), 317–325.
7. Elzayat, E.A., Elhilali, M.M., Holmium laser enucleation of the prostate (HoLEP): the endourologic alternative to open prostatectomy. Eur Urol 49 (2006), 87–91.
8. Kuntz, R.M., Current role of lasers in the treatment of benign prostatic hyperplasia (BPH). Eur Urol 49 (2006), 961–969.
9. Naspro, R., Bachmann, A., Gilling, P., et al. A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol 55 (2009), 1345–1357.
10. Kluivers, K.B., Riphagen, I., Vierhout, M.E., Brolmann, H.A., de Vet, H.C., Systematic review on recovery specific quality-of-life instruments. Surgery 143 (2008), 206–215.
11. Myles, P.S., Hunt, J.O., Nightingale, C.E., et al. Development and psychometric testing of a quality of recovery score after general anesthesia and surgery in adults. Anesth Analg 88 (1999), 83–90.
12. Saemi, A.M., Folsom, J.B., Plante, M.K., Injection therapy for prostatic disease: A renaissance concept. Indian J Urol 24 (2008), 329–335.
13. Andersson, K.E., Treatment of lower urinary tract symptoms: agents for intraprostatic injection. Scand J Urol 47 (2013), 83–90.
14. Magistro, G., Stief, C.G., Gratzke, C., New intraprostatic injectables and prostatic urethral lift for male LUTS. Nat Rev Urol 12 (2015), 461–471.
15. Karsenty, G., Denys, P., Amarenco, G., et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 53 (2008), 275–287.
16. Dykstra, D.D., Sidi, A.A., Scott, A.B., Pagel, J.M., Goldish, G.D., Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139 (1988), 919–922.
17. Smith, C.P., Radziszewski, P., Borkowski, A., Somogyi, G.T., Boone, T.B., Chancellor, M.B., Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 64 (2004), 871–875 discussion 5.
18. Chartier-Kastler, E., Mehnert, U., Denys, P., Giuliano, F., Botulinum neurotoxin A for male lower urinary tract symptoms. Curr Opin Urol 21 (2011), 13–21.
19. Mangera, A., Andersson, K.E., Apostolidis, A., et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 60 (2011), 784–795.
20. Mangera, A., Apostolidis, A., Andersson, K.E., et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol 65 (2014), 981–990.
21. Oeconomou, A., Madersbacher, H., Botulinum neurotoxin A for benign prostatic hyperplasia. Curr Opin Urol 20 (2010), 28–36.
22. Oeconomou, A., Madersbacher, H., Kiss, G., Berger, T.J., Melekos, M., Rehder, P., Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. European urology 54:4 (2008), 765–775.
23. Marberger, M., Chartier-Kastler, E., Egerdie, B., Lee, K.S., Grosse, J., Bugarin, D., et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol 63 (2013), 496–503.
24. Maria, G., Brisinda, G., Civello, I.M., Bentivoglio, A.R., Sganga, G., Albanese, A., Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62 (2003), 259–264 discussion 64-5.
25. McVary, K.T., Roehrborn, C.G., Chartier-Kastler, E., et al. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 192 (2014), 150–156.
26. Shim, S.R., Cho, Y.J., Shin, I.S., Kim, J.H., Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis. Int Urol Nephrol 48 (2016), 19–30.
27. Shore, N., NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 19 (2010), 305–310.
28. Shore, N., Cowan, B., The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis 2 (2011), 377–383.
29. Shore, N., Cowan, B.E., Wachs, B.H., Cline, K.J., Kalota, S.J., Freedman, S.J., Multi-center prospective randomized double-blind study of single-injection transrectal NX-1207 in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Annual Meeting of the South Central Section of the American Urological Association, Boston; September 10, 2007.
30. Cowan, B., et al. Outcome analysis 8-19 months after single treatment with transrectal NX-1207 in multi-center prospective blinded randomized placebo controlled study of men with lower urinary tract symptoms due to benign prostatic hyperplasia. Annual Meeting of the Mid-Atlantic Section of the American Urological Association, Bermuda; October 18, 2007.
31. Shore, N., et al. A prospective randomized two dose level comparison of single-injection transrectal intraprostatic NX-1207 and finasteride in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Annual Meeting of the North Central Section of the American Urological Association, Chicago; September 25, 2008.
32. Buckley, J.T., The channel-forming toxin aerolysin. FEMS Microbiol Immunol 5 (1992), 13–17.
33. Christensson, A., Laurell, C.B., Lilja, H., Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194 (1990), 755–763.
34. Froehner, M., Hakenberg, O.W., Koch, R., Schmidt, U., Meye, A., Wirth, M.P., Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer. Urol Int 76 (2006), 27–30.
35. Savblom, C., Malm, J., Giwercman, A., Nilsson, J.A., Berglund, G., Lilja, H., Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. Prostate 65 (2005), 66–72.
36. Singh, R., Browning, J.L., Abi-Habib, R., et al. Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anticancer Drugs 18 (2007), 809–816.
37. Williams, S.A., Merchant, R.F., Garrett-Mayer, E., Isaacs, J.T., Buckley, J.T., Denmeade, S.R., A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 99 (2007), 376–385.
38. Denmeade, S.R., Egerdie, B., Steinhoff, G., Merchant, R., Abi-Habib, R., Pommerville, P., Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 59 (2011), 747–754.
39. Elhilali, M.M., Pommerville, P., Yocum, R.C., Merchant, R., Roehrborn, C.G., Denmeade, S.R., Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J Urol 189 (2013), 1421–1426.
40. Porpiglia, F., Fiori, C., Bertolo, R., Garrou, D., Cattaneo, G., Amparore, D., Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int 116 (2015), 278–287.
41. McNicholas, T.A., Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system. Med Devices (Auckl) 9 (2016), 115–123.
42. McNicholas, T.A., Woo, H.H., Chin, P.T., et al. Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol 64 (2013), 292–299.
43. Roehrborn, C.G., Gange, S.N., Shore, N.D., et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol 190 (2013), 2161–2167.
44. Roehrborn, C., Gange, S., Shore, N., et al. Nr. 192: Long term (5 year) results from the largest, prospective, randomized, controlled study of the minimally invasive prostatic urethral lift (PUL). Eur Urol Suppl, 16, 2017, e334.
45. Sonksen, J., Barber, N.J., Speakman, M.J., et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol 68 (2015), 643–652.
46. Gratzke, C., Barber, N., Speakman, M.J., et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int 119 (2017), 767–775.
47. Cantwell, A.L., Bogache, W.K., Richardson, S.F., et al. Multicentre prospective crossover study of the ‘prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int 113 (2014), 615–622.
48. Chin, P.T., Bolton, D.M., Jack, G., et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 79 (2012), 5–11.
49. McVary, K.T., Gange, S.N., Shore, N.D., et al. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med 11 (2014), 279–287.
50. Perera, M., Roberts, M.J., Doi, S.A., Bolton, D., Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol 67 (2015), 704–713.
51. Roehrborn, C.G., Rukstalis, D.B., Barkin, J., et al. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol 22 (2015), 7772–7782.
52. Shore, N., Freedman, S., Gange, S., et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. Can J Urol 21 (2014), 7094–7101.
53. Woo, H.H., Bolton, D.M., Laborde, E., et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 9 (2012), 568–575.
54. Woo, H.H., Chin, P.T., McNicholas, T.A., et al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108 (2011), 82–88.
55. Rukstalis, D., Rashid, P., Bogache, W., et al. Two year durability after crossover to the prostatic urethral lift from randomized, blinded sham. BJU Int 118 (2016), 14–22.
56. Sturch, P., Woo, H.H., McNicholas, T., Muir, G., Ejaculatory dysfunction after treatment for lower urinary tract symptoms: retrograde ejaculation or retrograde thinking?. BJU Int 115 (2015), 186–187.
57. MacRae, C., Gilling, P., How I do it: aquablation of the prostate using the AQUABEAM system. Can J Urol 23 (2016), 8590–8593.
58. Gilling, P., Reuther, R., Kahokehr, A., Fraundorfer, M., Aquablation – image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int 117 (2016), 923–929.
59. Gilling, P., Anderson, P., Tan, A., Aquablation of the prostate for symptomatic benign prostatic hyperplasia: one-year results. J Urol 197 (2017), 1565–1572.
60. Dixon, C.M., Rijo Cedano, E., Mynderse, L.A., Larson, T.R., Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezum system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol 7 (2015), 13–18.
61. Mynderse, L.A., Hanson, D., Robb, R.A., et al. Rezum system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology 86 (2015), 122–127.
62. Dixon, C., Cedano, E.R., Pacik, D., et al. Efficacy and safety of rezum system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 86 (2015), 1042–1047.
63. McVary, K.T., Gange, S.N., Gittelman, M.C., et al. minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 195 (2016), 1529–1538.
64. McVary, K.T., Gange, S.N., Gittelman, M.C., et al. Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study. J Sex Med 13 (2016), 924–933.
65. Roehrborn, C.G., Gange, S.N., Gittelman, M.C., et al. Convective radiofrequency water vapor thermal therapy with rezum system: durable two-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol 197 (2017), 1507–1516.
66. DeMeritt, J.S., Elmasri, F.F., Esposito, M.P., Rosenberg, G.S., Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization. J Vasc Interv Radiol 11 (2000), 767–770.
67. Jones, P., Rai, B.P., Nair, R., Somani, B.K., Current status of prostate artery embolization for lower urinary tract symptoms: review of world literature. Urology 86 (2015), 676–681.
68. Bilhim, T., Pisco, J., Rio Tinto, H., et al. Unilateral versus bilateral prostatic arterial embolization for lower urinary tract symptoms in patients with prostate enlargement. Cardiovasc Intervent Radiol 36 (2013), 403–411.
69. Moreira, A.M., Marques, C.F., Antunes, A.A., et al. Transient ischemic rectitis as a potential complication after prostatic artery embolization: case report and review of the literature. Cardiovasc Intervent Radiol 36 (2013), 1690–1694.
70. Wang, M., Zhang, G., Yuan, K., Duan, F., Yan, J., Wang, Y., Seminal vesicle ischemia: an unusual complication occurring after prostatic artery embolization for the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol 26 (2015), 1580–1582.
71. Pisco, J.M., Rio Tinto, H., Campos Pinheiro, L., et al. Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up. Eur Radiol 23 (2013), 2561–2572.
72. Carnevale, F.C., da Motta-Leal-Filho, J.M., Antunes, A.A., et al. Quality of life and clinical symptom improvement support prostatic artery embolization for patients with acute urinary retention caused by benign prostatic hyperplasia. J Vasc Interv Radiol 24 (2013), 535–542.
73. Laborda, A., De Assis, A.M., Ioakeim, I., Sanchez-Ballestin, M., Carnevale, F.C., De Gregorio, M.A., Radiodermitis after prostatic artery embolization: case report and review of the literature. Cardiovasc Intervent Radiol 38 (2015), 755–759.
74. Antunes, A.A., Carnevale, F.C., da Motta Leal Filho, J.M., et al. Clinical, laboratorial, and urodynamic findings of prostatic artery embolization for the treatment of urinary retention related to benign prostatic hyperplasia. A prospective single-center pilot study. Cardiovasc Intervent Radiol 36 (2013), 978–986.
75. Bagla, S., Martin, C.P., van Breda, A., et al. Early results from a United States trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol 25 (2014), 47–52.
76. de Assis, A.M., Moreira, A.M., de Paula Rodrigues, V.C., et al. Prostatic artery embolization for treatment of benign prostatic hyperplasia in patients with prostates > 90 g: a prospective single-center study. J Vasc Interv Radiol 26 (2015), 87–93.
77. 3: results from a single-center prospective study. Urology 84 (2014), 400–404.
78. Somani, B.K., Hacking, N., Bryant, T., et al. Prostate artery embolization (PAE) for benign prostatic hyperplasia (BPH). BJU Int 114 (2014), 639–640.
79. Wang, M., Guo, L., Duan, F., et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates. BJU Int 117 (2016), 155–164.
80. Li, Q., Duan, F., Wang, M.Q., Zhang, G.D., Yuan, K., Prostatic arterial embolization with small sized particles for the treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia: preliminary results. Chin Med J (Engl) 128 (2015), 2072–2077.
81. Pisco, J., Bilhim, T., Pinheiro, L.C., et al. Prostate embolization as an alternative to open surgery in patients with large prostate and moderate to severe lower urinary tract symptoms. J Vasc Interv Radiol 27 (2016), 700–708.
82. Pisco, J.M., Bilhim, T., Pinheiro, L.C., et al. Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol 27 (2016), 1115–1122.
83. Carnevale, F.C., Iscaife, A., Yoshinaga, E.M., Moreira, A.M., Antunes, A.A., Srougi, M., Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (bph): preliminary results of a single center, prospective, urodynamic-controlled analysis. Cardiovasc Intervent Radiol 39 (2016), 44–52.
84. Gao, Y.A., Huang, Y., Zhang, R., et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate–a prospective, randomized, and controlled clinical trial. Radiology 270 (2014), 920–928.
85. Russo, G.I., Kurbatov, D., Sansalone, S., et al. Prostatic arterial embolization vs open prostatectomy: a 1-year matched-pair analysis of functional outcomes and morbidities. Urology 86 (2015), 343–348.
86. Shim, S.R., Kanhai, K.J., Ko, Y.M., Kim, J.H., Efficacy and safety of prostatic arterial embolization: systematic review with meta-analysis and meta-regression. J Urol 197 (2017), 465–479.